Edition:
United Kingdom

Guerbet SA (GRBT.PA)

GRBT.PA on Paris Stock Exchange

74.37EUR
4:26pm GMT
Change (% chg)

€0.31 (+0.42%)
Prev Close
€74.06
Open
€73.39
Day's High
€75.74
Day's Low
€72.04
Volume
9,139
Avg. Vol
7,181
52-wk High
€90.64
52-wk Low
€66.80

Select another date:

Wed, Dec 6 2017

BRIEF-Guerbet Updates On MHLW Decision In Japan

* HAS IMMEDIATELY PROCEEDED TO REQUESTED REVISION OF PRECAUTIONS FOR MAGNESCOPE Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Guerbet 9 months revenue up at ‍​601.4 million euros

* 9 MONTHS REVENUE AT CURRENT EXCHANGE RATE EUR ‍​601.4 MILLION VERSUS EUR 568.4 MILLION YEAR AGO

BRIEF-Guerbet H1 net income up at 23.1 million euros

* H1 NET INCOME EUR 23.1 MILLION VERSUS EUR 12.1 MILLION YEAR AGO

BRIEF-Guerbet announces CE mark for Vectorio

* REG-GUERBET ANNOUNCES CE MARK FOR VECTORIO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-FDA approves Guerbet’S Dotarem for patients younger than two years‍​

* FDA APPROVES GUERBET’S DOTAREM (GADOTERATE MEGLUMINE) FOR PEDIATRIC PATIENTS YOUNGER THAN TWO YEARS‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Guerbet H1 revenue rises to 407.1 million euros

* H1 REVENUE EUR 407.1 MILLION VERSUS EUR 376.7 MILLION YEAR AGO

BRIEF-Guerbet to phase out Hexabrix and Optimark sales globally

* WILL PHASE OUT SALES THROUGHOUT WORLD OF TWO PRODUCTS: HEXABRIX® (MEGLUMINE AND SODIUM IOXAGLATE) AND OPTIMARK® (GADOVERSETAMIDE).

Select another date: